

What Clinicians Want to Know: First-Line and Maintenance Therapy for Patients with ER-Positive, HER2-Positive Metastatic Breast Cancer — Part 1 of 2

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- In the Phase III DESTINY-Breast09 trial, a progression-free survival (PFS) benefit was observed with trastuzumab deruxtecan (T-DXd)/pertuzumab versus docetaxel/trastuzumab/pertuzumab for which subgroup of patients with HER2-positive advanced breast cancer?**
 - Only those patients with hormone receptor (HR)-positive disease
 - Only those patients with HR-negative disease
 - Both patients with HR-positive disease and those with HR-negative disease
- What proportion of patients with HR-positive disease who were enrolled in the T-DXd/pertuzumab study arm of the DESTINY-Breast09 trial received concurrent endocrine therapy (ET) during the maintenance phase of the trial?**
 - 2.3%
 - 13.5%
 - 33.6%
 - 64.7%
- In the Phase III PATINA trial, patients with HR-positive, HER2-positive advanced breast cancer who received maintenance therapy with palbociclib combined with anti-HER2 therapy and ET experienced which of the following PFS outcomes in comparison to patients on the control arm?**
 - An approximate 8-month prolongation
 - An approximate 15-month prolongation
 - An approximate 23-month prolongation
 - Inferior outcomes
- In the Phase III HER2CLIMB-05 trial, which patient group with HER2-positive locally advanced or metastatic breast cancer experienced a doubling in PFS with tucatinib combined with trastuzumab and pertuzumab as maintenance therapy in comparison to the control arm?**
 - Patients with HR-positive disease
 - Patients with HR-negative disease
 - Both patients with HR-positive disease and those with HR-negative disease
- The ongoing placebo-controlled Phase III INAVO122 trial is comparing inavolisib combined with trastuzumab and pertuzumab to trastuzumab and pertuzumab in which setting?**
 - As first-line induction therapy for patients with HER2-low disease and a PIK3CA mutation
 - As first-line induction therapy for patients with HER2-positive disease and a PIK3CA mutation
 - As maintenance therapy for patients with HER2-low disease and a PIK3CA mutation
 - As maintenance therapy for patients with HER2-positive disease and a PIK3CA mutation